Comparative Diagnostic Yield of Endobronchial Cryo Biopsy vs Forceps Biopsy in Patients With Suspected Sarcoidosis

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorSanjay Gandhi Postgraduate Institute of Medical Sciences

About this trial

Sarcoidosis is a multi-systemic granulomatous disease of unknown cause that is characterized by the formation of non-caseous epithelioid cell granulomas. Sarcoidosis involves the respiratory system in \> 90% of cases, usually the hilar and mediastinal nodes, and, less frequently, the lung tissue. Airway involvement, as judged by clinical features, physiologic testing, imaging techniques, bronchoscopy, and airway mucosal biopsy, has been observed in nearly two-thirds of patients with sarcoidosis. Although sarcoidosis involving thoracic lymph nodes and pulmonary parenchyma is familiar to most clinicians, airway involvement is often overlooked. The frequency of airway involvement increases as the parenchymal disease progresses, and\\airway involvement is associated with increased morbidity, respiratory symptoms, and mortality. The initial airway abnormality is the inflammation manifested by mucosal edema, erythema, and the formation of granulomas. As the airway disease progresses, the mucosa may demonstrate granularity, nodularity, cobble stoning, and friability. Sarcoid granulomas tend to develop along the bronchovascular bundle or in the vicinity of the airways. Overall quality of the endobronchial biopsy (EBB) will depend on the method by which it is obtained and cryo-EBB will most likely to provide better tissue for the diagnosis in comparison to forceps biopsy which has smaller sample as well as crush artifacts. Therefore, it is hypothesized that cryo-EBB will be better than forceps EBB and combined together it will increase the overall diagnostic yield of the sarcoidosis when combined with lymph node sampling by endobronchial ultrasound guided trans-bronchial needle aspiration (EBUS-TBNA).

1. Primary objective: To compare the diagnostic yield of cryo-EBB with forceps biopsy in patients undergoing routine EBUS-TBNA for suspected sarcoidosis. 2. Secondary Objective: To evaluate the overall diagnostic yield of combined endobronchial biopsy and EBUS-TBNA in patients undergoing routine EBUS-TBNA for suspected sarcoidosis.

The relevance and the expected outcome of the proposed study

1. The study will provide insight to obtain an endobronchial biopsy either with cryo probe or forceps 2. The study will also provide information regarding overall increase in diagnostic yield if any when the endobronchial biopsies are combined with EBUS-TBNA.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

Patient age less than 18 years

Patients with co-morbid conditions like Diabetes mellitus, renal failure, chronic liver disease or any other chronic disease.

Patients already on treatment with steroids or h/o steroids intake in last three months or on disease modifying and immunosuppressive drugs.

Final Diagnosis other than sarcoidosis

Trial design

Design model

Parallel

Treatments tested in this trial

  • Cryobiopsy with liquid nitrogen

    Device

    Forceps vs Cryo Endobronchial Biopsy

  • Endobronchial Forceps Biopsy

    Device

    Comparision of forceps and cryo endobronchial biopsy

Treatment groups

150 Participants
are divided into 2 treatment groups
Group A: Cryo-Endobronchial BiopsyExperimental treatment 1 intervention
Group B: Forceps Endobronchial BiopsyActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Diagnostic Yield

To compare the diagnostic yield of cryo-endobronchial biopsy with forceps biopsy in patients undergoing routine EBUS-TBNA for suspected sarcoidosis.

Time frame
Two week after the end of enrollment

Secondary outcomes

1

Over all diagnostic yield

Overall diagnostic yield - TBNA + Endobronchial Biopsy

Time frame
Two week after the end of enrollment
2

Complications

Complications of endobronchial biopsy

Time frame
From enrollment to Two week after the end of enrollment
3

Dignostic yield based on endobronchial abnormality

Diagnostic yield in normal vs abnormal endobronchial fingins

Time frame
Two week after the end of enrollment

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.